title: Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent.
abstract: OBJECTIVE
  The BiodivYsio stent is a new stent coated with phosphorylcholine, a biocompatible molecule designed to reduce the formation of thrombus and potentially the risk of restenosis. The feasibility, safety, and efficacy of elective and urgent implantation of this coated coronary stent were prospectively studied.
  
  
  RESULTS
  We studied 224 patients who underwent elective (67%) or bail-out implantation of 303 BiodivYsio stents in 286 lesions. Most lesions (62%) had unfavorable characteristics (type B2 or C) and half of them (50%) had thrombus and/or chronic total occlusion. Clinical follow-up was obtained in all patients at one month and in the first 132 patients at six months. Repeat angiography was undertaken in all patients with recurrent ischemia. Successful stent deployment was achieved in 284 lesions (99.3%). One emergency coronary artery bypass graft (CABG) was required. Angiographic success rate was 98.3% (281/286). There was 1 (0.4%) subacute stent thrombosis associated with Q-wave myocardial infarction and two (0.9%) in-hospital deaths. Reference vessel diameter was 2.82 +/- 0.32 mm. Minimum luminal diameter (MLD) increased from 0.38 +/- 0.25 mm to 2.97 +/- 0.35 mm and diameter stenosis decreased from 83.8 +/- 12.1% to 5.8 +/- 9.7%. Clinical restenosis rate was 6.1% (8/132 patients) at 6-month follow-up. Target vessel revascularization rate at 6-month follow-up was 5.4%.
  
  
  CONCLUSIONS
  This initial clinical experience indicates that the implantation of stents coated with phosphorylcholine appears to be safe and efficacious in the treatment of complex coronary lesions and is associated with an extremely low target vessel revascularization rate.
authors.affiliation: Department of Interventional Cardiology, Centre Médico-Chirurgical Parly-Grand Chesnay, Le Chesnay, France.
authors.forename: H
authors.initials: H
authors.lastname: Zheng
authors.forename: P
authors.initials: P
authors.lastname: Barragan
authors.forename: T
authors.initials: T
authors.lastname: Corcos
authors.forename: J B
authors.initials: JB
authors.lastname: Siméoni
authors.forename: X
authors.initials: X
authors.lastname: Favereau
authors.forename: P O
authors.initials: PO
authors.lastname: Roquebert
authors.forename: Y
authors.initials: Y
authors.lastname: Guérin
authors.forename: J
authors.initials: J
authors.lastname: Sainsous
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010767:Phosphorylcholine / Q000627:therapeutic use*; D011446:Prospective Studies; D015607:Stents; D013927:Thrombosis / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D020099:Coated Materials, Biocompatible; D010767:Phosphorylcholine